Interim Analysis of the Randomized Phase 1b/3 Study Evaluating the Safety and Efficacy of Tazemetostat Plus Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma

被引：5

作者：

Batlevi, Connie Lee ^{[1
]}

Park, Steven I. ^{[2
]}

Nastoupil, Loretta ^{[3
]}

Phillips, Tycel ^{[4
]}

Amengual, Jennifer E. ^{[5
]}

Andorsky, David ^{[6
]}

Campbell, Philip ^{[7
]}

McKay, Pamela ^{[8
]}

Pagel, John M. ^{[9
]}

Leonard, John P. ^{[10
]}

Yang, Jay ^{[11
]}

O'Connor, Heather ^{[11
]}

Hamlett, Anthony ^{[11
]}

Adib, Deyaa ^{[11
]}

Morschhauser, Franck ^{[12
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY USA

[2] Levine Canc Inst, Dept Hematol Oncol & Blood Disorders, Charlotte, NC USA

[3] MD Anderson Canc Ctr, Houston, TX USA

[4] Univ Michigan, Ann Arbor, MI USA

[5] Columbia Univ, Irving Med Ctr, New York, NY USA

[6] Rocky Mt Canc Ctr, Boulder, CO USA

[7] Univ Hosp Geelong, Barwon Hlth, Geelong, Vic, Australia

[8] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland

[9] Swedish Canc Inst, Ctr Blood Disorders & Stem Cell Transplantat, Seattle, WA USA

[10] Weill Cornell Med, New York, NY USA

[11] Epizyme Inc, Cambridge, MA USA

[12] Univ Lille, CHU Lille, EA 7365 GRITA Grp Rech Formes Injectables & Tec, F-59000 Lille, France

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-148199

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2207

引用

页数：6

共 50 条

[21] Phase IIIb randomized study of lenalidomide plus rituximab (R2) followed by maintenance in relapsed/refractory NHL: Analysis of patients with double-refractory or early relapsed follicular lymphoma (FL).
Andorsky, David Jacob
Yacoub, Abdulraheem
Melear, Jason M.
Coleman, Morton
Kolibaba, Kathryn S.
Brooks, Heather Dawn
Bitran, Jacob D.
Fanning, Suzanne R.
Lansigan, Frederick
Ricker, Justin L.
Foon, Kenneth A.
Liu, Dongfang
Llorente, Mary
Li, Jiahui
Sharman, Jeff Porter
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[22] Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study
Diefenbach, Catherine
Kahl, Brad S.
McMillan, Andrew
Briones, Javier
Banerjee, Lalita
Cordoba, Raul
Miall, Fiona
Burke, John M.
Hirata, Jamie
Jiang, Yanwen
Paulson, Joseph N.
Chang, Yi Meng
Musick, Lisa
Abrisqueta, Pau
LANCET HAEMATOLOGY, 2021, 8 (12): : E891 - E901
[23] Acalabrutinib in combination with rituximab and lenalidomide in patients with relapsed or refractory follicular lymphoma: Results of the phase 1b open-label study (ACE-LY-003)
Strati, Paolo
Agajanian, Richy
Lossos, Izidore S.
Coleman, Morton
Kridel, Robert
Wood, Andrew
Lesley, Robin
Wun, Chuan-Chuan
Stephens, Deborah M.
BRITISH JOURNAL OF HAEMATOLOGY, 2025, 206 (03) : 887 - 898
[24] Subcutaneous Epcoritamab Combined With Rituximab plus Lenalidomide for the Treatment of Patients with Relapsed or Refractory Follicular Lymphoma: Phase 1/2 Trial Update
Lorenzo, Falchi
Sirpa, Leppa
Wahlin, Bjorn E.
Marcel, Nijland
Christensen, Jacob H.
De, Vos Sven
Harald, Holte
Linton, Kim M.
Aqeel, Abbas
Wang Liwei
Minh, Dinh
Brian, Elliott
David, Belada
AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 : S31 - S31
[25] Phase 1b Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis
Melani, Christopher
Lakhotia, Rahul
Pittaluga, Stefania
Miljkovic, Milos D.
Muppidi, Jagan R.
Portell, Craig A.
Farah, Rafic
Lee, Seung Tae
Juanitez, Anna Marie
Chou, Lydia L.
Steinberg, Seth M.
Jaffe, Elaine S.
Staudt, Louis
Roschewski, Mark
Wilson, Wyndham
BLOOD, 2019, 134
[26] Efficacy and Safety of Tisagenlecleucel in Adult Patients with Relapsed/Refractory Follicular Lymphoma: Interim Analysis of the Phase 2 Elara Trial
Fowler, Nathan H.
Dickinson, Michael
Dreyling, Martin
Martinez-Lopez, Joaquin
Kolstad, Arne
Butler, Jason P.
Ghosh, Monalisa
Popplewell, Leslie L.
Chavez, Julio C.
Bachy, Emmanuel
Kato, Koji
Harigae, Hideo
Kersten, Marie Jose
Andreadis, Charalambos
Riedell, Peter A.
Ho, Joy
Perez-Simon, Jose Antonio
Nagle, Sarah J.
Nastoupil, Loretta J.
von Tresckow, Bastian
Ferreri, Andres J. M.
Teshima, Takanori
Patten, Piers
McGuirk, Joseph P.
Petzer, Andreas
Offner, Fritz C.
Viardot, Andreas
Zinzani, Pier Luigi
Malladi, Ram
Pacaud, Lida Bubuteishvili
Forcina, Alessandra
Zia, Aiesha
Schuster, Stephen J.
Thieblemont, Catherine
BLOOD, 2020, 136
[27] Efficacy and Safety of Tisagenlecleucel in Adult Patients With Relapsed/Refractory Follicular Lymphoma: Interim Analysis of the Phase 2 ELARA Trial
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 12 - 13
[28] AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma
Leonard, John P.
Trneny, Marek
Izutsu, Koji
Fowler, Nathan H.
Hong, Xiaonan
Zhu, Jun
Zhang, Huilai
Offner, Fritz
Scheliga, Adriana
Nowakowski, Grzegorz S.
Pinto, Antonio
Re, Francesca
Fogliatto, Laura Maria
Scheinberg, Phillip
Flinn, Ian W.
Moreira, Claudia
Cabecadas, Jose
Liu, David
Kalambakas, Stacey
Fustier, Pierre
Wu, Chengqing
Gribben, John G.
Calaminici, Maria
Copie-Bergman, Christiane
Lopez-Guillermo, Armando
O'Connor, Owen
Williams, Michael
Suciu, Stefan
Levine, Benjamin
Kern, Julie
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (14) : 1188 - +
[29] A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma
Martin, Thomas
Baz, Rachid
Benson, Don M.
Lendvai, Nikoletta
Wolf, Jeffrey
Munster, Pamela
Lesokhin, Alexander M.
Wack, Claudine
Charpentier, Eric
Campana, Frank
Vij, Ravi
BLOOD, 2017, 129 (25) : 3294 - 3303
[30] Lenalidomide-Rituximab or Lenalidomide-Rituximab-Bendamustine in Patients with Relapsed/Refractory Follicular Lymphoma: Priimary Analysis of the Randomized Phase II HOVON110/Rebel Trial
Kersten, Marie Jose
Dreyling, Martin
Linton, Kim M.
Chitu, Dana
Tonino, Sanne
Kap, Marcel
Liu, Roberto D.
Chamuleau, Martine E. D.
Visser, Hein P. J.
De Jongh, Eva
Marijt, Erik Waf
Leijs, Maria B. L.
Bilgin, Yavuz M.
Duerig, Jan
McKay, Pamela
Snijders, Tjeerd J. F.
Pettitt, Andrew
Minnema, Monique C.
Prange-Krex, Gabriele
Cuijpers, Maria
Boehmer, Lara H.
Tick, Lidwine W.
Florschuetz, Axel
Silbermann, Matthijs
Fijnheer, Rob
Beeker, Aart
Tolboom, Nelleke
Mitea, Cristina
Arens, Anne I. J.
Zwezerijnen, Gerben J. C.
Klapper, Wolfram
Coupland, Sarah E.
de Jong, Daphne
Doorduijn, Jeanette K.
Zijlstra, Josee M.
BLOOD, 2022, 140 : 2283 - 2285

← 1 2 3 4 5 →